US stock futures dip as Nvidia earnings spark little cheer
WASHINGTON, D.C. — Mihael Hristos Polymeropoulos, President and CEO of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), has acquired 10,000 shares of the company’s common stock, according to a recent filing with the Securities and Exchange Commission. The shares were purchased on February 25 at a weighted average price of $4.464, totaling approximately $44,640. The purchase comes as the $260 million market cap company maintains impressive gross profit margins of 94% and a strong liquidity position with a current ratio of 4.39.
The transaction was executed over multiple trades at prices ranging from $4.445 to $4.48 per share. Following this acquisition, Polymeropoulos now directly owns 2,331,730 shares of Vanda Pharmaceuticals. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value estimates, with analyst targets ranging from $5 to $20 per share.
Polymeropoulos, who also serves as Chairman of the Board, continues to hold a significant position in the company, reflecting his ongoing confidence in Vanda Pharmaceuticals’ future prospects. InvestingPro analysis reveals several positive indicators, including a strong balance sheet with more cash than debt, and analysts expect the company to return to profitability this year. Discover more insights about VNDA and 1,400+ other stocks with InvestingPro’s comprehensive research reports.
In other recent news, Vanda Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of -$0.08, compared to the forecasted -$0.17. The company also exceeded revenue forecasts, reporting $53.2 million against the expected $51.23 million. Vanda Pharmaceuticals has set its 2025 revenue guidance to range between $210 million and $250 million. Analysts at H.C. Wainwright have adjusted their financial outlook on Vanda, increasing the price target to $20.00 from $18.00, while maintaining a Buy rating. Cantor Fitzgerald also reiterated its Overweight rating and $13.00 price target for the company, citing a positive outlook on its future.
Additionally, Vanda Pharmaceuticals disclosed changes to its executive compensation, including adjustments to annual bonuses and base salaries, as well as the awarding of restricted stock units. The company announced the development of a novel antisense oligonucleotide therapeutic, VCA-894A, targeting Charcot-Marie-Tooth disease Type 2S. This therapy has been granted orphan designation by the FDA. The company also entered into an exclusive global license agreement for imsidolimab, an IL36 receptor antagonist monoclonal antibody, with plans to initiate and complete technology transfer activities in 2025. These developments reflect Vanda’s commitment to advancing its pipeline and addressing unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.